<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554890</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696BUS01</org_study_id>
    <nct_id>NCT02554890</nct_id>
  </id_info>
  <brief_title>Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.</brief_title>
  <acronym>PIONEER-HF</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the effect of in-hospital initiation of
      sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP
      in patients who have been stabilized following hospitalization for acute decompensated heart
      failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤
      40%).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2016</start_date>
  <completion_date type="Actual">July 24, 2018</completion_date>
  <primary_completion_date type="Actual">June 29, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Time-averaged Change From Baseline</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>To assess the effect of in-hospital initiation of sacubitril/valsartan vs. enalapril on the time-averaged percentage change of NT-proBNP from baseline in patients who have been stabilized following hospitalization for ADHF and reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤ 40%) between week 4 and 8.
Number of patients with both a baseline value and a value at Week 4 or Week 8. Plasma NT-proBNP (pg/mL) values were averaged from Week 4 and Week 8 visits. N-terminal pro b-type natriuretic peptide (NTproBNP) are peptide (small proteins) that are either hormones or part of the peptide that contained the hormone at one time. They are continually produced in small quantities in the heart and released in larger quantities when the heart senses that it needs to work harder, as in heart failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Incidences of Symptomatic Hypotension</measure>
    <time_frame>8 weeks of treatment</time_frame>
    <description>Examine the effect of LCZ696 vs. enalapril on incidence of symptomatic hypotension during 8 weeks of treatment Hypotension is low blood pressure. Patients with hypotension may experience symptoms when their blood pressure drops, compared to the patient's normal values. Symptoms of hypotension can include dizziness, lightheadedness, blurred vision, weakness, fatigue, nausea, palpitations, and headache.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Incidences of Hyperkalemia</measure>
    <time_frame>8 weeks of treatment</time_frame>
    <description>Hyperkalemia is defined as Potassium level &gt;5.5 mEq/L. Hyperkalemia is the medical term that describes a potassium level in your blood that's higher than normal. Potassium is a chemical that is critical to the function of nerve and muscle cells, including those in your heart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Incidences of Angioedema</measure>
    <time_frame>8 weeks of treatment</time_frame>
    <description>Angioedema is a type of abrupt swelling that occurs under the skin and/or mucous membranes and is often localized to the head, neck, throat, and/or tongue, but may occur elsewhere, including the genitalia and intestines. Severe cases may be associated with difficulty in breathing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Sensitivity Troponin (Hs-Troponin)</measure>
    <time_frame>Baseline, Week 4/Week 8</time_frame>
    <description>time-averaged (Weeks 4 and 8) change from baseline in hs-troponin T. hs-Troponin-T is a biomarker that is released from the heart under stress or injury conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary cGMP</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>Time-averaged (Weeks 4 and 8) change from baseline in urinary cGMP. Urinary Cyclic GMP (cGMP) is a biomarker measured in the urine that reflects the activity of biomarkers such as BNP (Brain Natriuretic Peptide)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary cGMP to Urinary Creatinine Ratio</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>Time-averaged (Weeks 4 and 8) change from baseline in urinary cGMP to urinary creatinine ratio.
Urinary cGMP to urinary creatinine ratio is how much urinary cGMP (which reflects natriuretic peptide activity) compared to a compound in the urine called creatinine (which helps your doctor evaluate how well your kidneys are functioning).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in BNP to NTproBNP Ratio</measure>
    <time_frame>baseline, Week 4 and Week 8</time_frame>
    <description>Time-averaged (Weeks 4 and 8) change from baseline in BNP to NT-proBNP ratio. BNP and NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure. The test measuring BNP to NT-proBNP is measuring how much of each of these biomarkers are present in order to evaluate heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Change From Baseline at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>BNP and NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure. The test measuring BNP to NT-proBNP is measuring how much of each of these biomarkers are present in order to evaluate heart failure.
Plasma NT-proBNP (pg/mL) values were Week 8 visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">887</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>sacubitril/valsartan (LCZ696)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enalapril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sacubitril/valsartan (LCZ696)</intervention_name>
    <description>sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.</description>
    <arm_group_label>sacubitril/valsartan (LCZ696)</arm_group_label>
    <other_name>LCZ696</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.</description>
    <arm_group_label>Enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sacubitril/valsartan (LCZ696) matching placebo</intervention_name>
    <description>matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.</description>
    <arm_group_label>Enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enalapril matching placebo</intervention_name>
    <description>enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.</description>
    <arm_group_label>sacubitril/valsartan (LCZ696)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Possess the capacity to provide written informed consent which must be obtained before
             any assessment is performed.

          2. Currently hospitalized for ADHF. Patients with a diagnosis of acute heart failure had
             to have symptoms and signs of fluid overload (i.e. jugular venous distention, edema or
             rales on auscultation or pulmonary congestion on chest x-ray) at time of
             hospitalization.

          3. Eligible patients will be randomized no earlier than 24 hours and up to ten days after
             presentation while still hospitalized as long as meet the following definition of
             stable status:

               -  SBP ≥100mm Hg for the preceding 6 hours prior to randomization; no symptomatic
                  hypotension

               -  No increase (intensification) in i.v. diuretic dose within last 6 hours prior to
                  randomization

               -  No i.v. inotropic drugs for 24 hours prior to randomization

               -  No i.v. vasodilators including nitrates within last 6 hours prior to
                  randomization

          4. LVEF ≤40% within the past 6 months (including current hospitalization) using
             echocardiography, multi gated acquisition scan (MUGA), CT scanning, MRI or ventricular
             angiography, provided no subsequent study documented an EF of &gt;40%.

          5. Elevated NT-proBNP ≥ 1600pg/mL OR BNP ≥400 pg/mL during current hospitalization.

        Key Exclusion Criteria:

          1. Currently taking sacubitril/valsartan tablets or any use within the past 30 days.

          2. Enrollment in any other clinical trial involving an investigational agent or
             investigational device.

          3. History of hypersensitivity, known or suspected contraindications, or intolerance to
             any of the study drugs, including ACEIs, ARBs, or Sacubitril (NEP inhibitor).

          4. Patients with a known history of angioedema related to previous ACE inhibitor or ARB
             therapy.

          5. Requirement of treatment with both ACE inhibitor and ARB.

          6. eGFR &lt; 30 ml/min/1.73 m2 as measured by the simplified Modification of Diet in Renal
             Disease (MDRD) formula at screening.

          7. Serum potassium &gt; 5.2 mEq/L at screening.

          8. Known hepatic impairment (as evidenced by total bilirubin &gt; 3 mg/dL, or increased
             ammonia levels, if performed), or history of cirrhosis with evidence of portal
             hypertension such as varices

          9. Acute coronary syndrome, stroke, transient ischemic attack; cardiac, carotid or other
             major CV surgery; percutaneous coronary intervention (PCI) or carotid angioplasty,
             within one month prior to Visit 1.

         10. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test.

         11. Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, including women whose career, lifestyle, or sexual orientation
             precludes intercourse with a male partner and women whose partners have been
             sterilized by vasectomy or other means, UNLESS they are using two birth control
             methods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817-1460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Marino</city>
        <state>California</state>
        <zip>91108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Pablo</city>
        <state>California</state>
        <zip>94806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209-6511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>34667</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33881</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303-3400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Indiana</state>
        <zip>47374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103-3117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elmer</city>
        <state>New Jersey</state>
        <zip>08318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <zip>08035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Natrona Heights</city>
        <state>Pennsylvania</state>
        <zip>15065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102 2293</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-1615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018 Apr;198:145-151. doi: 10.1016/j.ahj.2018.01.004. Epub 2018 Jan 10.</citation>
    <PMID>29653636</PMID>
  </reference>
  <reference>
    <citation>Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum in: N Engl J Med. 2019 Mar 14;380(11):1090.</citation>
    <PMID>30415601</PMID>
  </reference>
  <reference>
    <citation>Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation. 2019 May 7;139(19):2285-2288. doi: 10.1161/CIRCULATIONAHA.118.039331.</citation>
    <PMID>30955360</PMID>
  </reference>
  <reference>
    <citation>Morrow DA, Velazquez EJ, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, Rocha R, Braunwald E. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J. 2019 Oct 21;40(40):3345-3352. doi: 10.1093/eurheartj/ehz240.</citation>
    <PMID>31093657</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <results_first_submitted>July 19, 2019</results_first_submitted>
  <results_first_submitted_qc>September 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2019</results_first_posted>
  <disposition_first_submitted>January 16, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 16, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 17, 2019</disposition_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>reduced ejection fraction</keyword>
  <keyword>NTproBNP</keyword>
  <keyword>Heart failure with reduced ejection fraction (HFREF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02554890/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02554890/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 964 patients were screened for the study. Of these, 887 patients were randomized, 444 to enalapril and 443 to sacubitril/valsartan, and 875 randomized patients were treated.</recruitment_details>
      <pre_assignment_details>Patients were randomized 1:1 to sacubitril/valsartan or enalapril. At the end of the 8-week treatment period, all patients had a 36-hour washout from study treatment prior to starting the open-label extension to ensure that the blinding of the core study was maintained.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Enalapril</title>
          <description>Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)</description>
        </group>
        <group group_id="P2">
          <title>Sacubitril/Valsartan (LCZ696)</title>
          <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="444"/>
                <participants group_id="P2" count="443"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Patients</title>
              <participants_list>
                <participants group_id="P1" count="436"/>
                <participants group_id="P2" count="439"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="348"/>
                <participants group_id="P2" count="352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/Guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="887"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="835"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/Guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographic and baseline characteristics are in the Full analysis set (FAS) of treatment groups.
FAS: Patients who were randomized except those who were not qualified for randomization and have not received study treatment, but were inadvertently randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Enalapril</title>
          <description>Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)</description>
        </group>
        <group group_id="B2">
          <title>Sacubitril/Valsartan (LCZ696)</title>
          <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="441"/>
            <count group_id="B2" value="440"/>
            <count group_id="B3" value="881"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="363"/>
                    <measurement group_id="B2" value="370"/>
                    <measurement group_id="B3" value="733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="246"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="327"/>
                    <measurement group_id="B3" value="635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="399"/>
                    <measurement group_id="B2" value="405"/>
                    <measurement group_id="B3" value="804"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Time-averaged Change From Baseline</title>
        <description>To assess the effect of in-hospital initiation of sacubitril/valsartan vs. enalapril on the time-averaged percentage change of NT-proBNP from baseline in patients who have been stabilized following hospitalization for ADHF and reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤ 40%) between week 4 and 8.
Number of patients with both a baseline value and a value at Week 4 or Week 8. Plasma NT-proBNP (pg/mL) values were averaged from Week 4 and Week 8 visits. N-terminal pro b-type natriuretic peptide (NTproBNP) are peptide (small proteins) that are either hormones or part of the peptide that contained the hormone at one time. They are continually produced in small quantities in the heart and released in larger quantities when the heart senses that it needs to work harder, as in heart failure.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS): consisted of all randomized patients with the exception for those patients who had not been qualified for randomization and had not received study treatment, but had been inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)</description>
          </group>
          <group group_id="O2">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).</description>
          </group>
        </group_list>
        <measure>
          <title>N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Time-averaged Change From Baseline</title>
          <description>To assess the effect of in-hospital initiation of sacubitril/valsartan vs. enalapril on the time-averaged percentage change of NT-proBNP from baseline in patients who have been stabilized following hospitalization for ADHF and reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤ 40%) between week 4 and 8.
Number of patients with both a baseline value and a value at Week 4 or Week 8. Plasma NT-proBNP (pg/mL) values were averaged from Week 4 and Week 8 visits. N-terminal pro b-type natriuretic peptide (NTproBNP) are peptide (small proteins) that are either hormones or part of the peptide that contained the hormone at one time. They are continually produced in small quantities in the heart and released in larger quantities when the heart senses that it needs to work harder, as in heart failure.</description>
          <population>Full analysis set (FAS): consisted of all randomized patients with the exception for those patients who had not been qualified for randomization and had not received study treatment, but had been inadvertently randomized into the study.</population>
          <units>pg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7466" lower_limit="0.6842" upper_limit="0.8147"/>
                    <measurement group_id="O2" value="0.5333" lower_limit="0.4890" upper_limit="0.5816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>ANCOVA model for a log-scaled response with treatment group as a class variable and biomarker baseline value in logarithmic scale as a continuous covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>expon. back transformed from LS means</param_type>
            <param_value>0.7143</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6315</ci_lower_limit>
            <ci_upper_limit>0.8080</ci_upper_limit>
            <estimate_desc>Geometric Mean Ratio: Sacubitril/ Valsartan vs. Enalapril</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Incidences of Symptomatic Hypotension</title>
        <description>Examine the effect of LCZ696 vs. enalapril on incidence of symptomatic hypotension during 8 weeks of treatment Hypotension is low blood pressure. Patients with hypotension may experience symptoms when their blood pressure drops, compared to the patient's normal values. Symptoms of hypotension can include dizziness, lightheadedness, blurred vision, weakness, fatigue, nausea, palpitations, and headache.</description>
        <time_frame>8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)</description>
          </group>
          <group group_id="O2">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Incidences of Symptomatic Hypotension</title>
          <description>Examine the effect of LCZ696 vs. enalapril on incidence of symptomatic hypotension during 8 weeks of treatment Hypotension is low blood pressure. Patients with hypotension may experience symptoms when their blood pressure drops, compared to the patient's normal values. Symptoms of hypotension can include dizziness, lightheadedness, blurred vision, weakness, fatigue, nausea, palpitations, and headache.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Incidences of Hyperkalemia</title>
        <description>Hyperkalemia is defined as Potassium level &gt;5.5 mEq/L. Hyperkalemia is the medical term that describes a potassium level in your blood that's higher than normal. Potassium is a chemical that is critical to the function of nerve and muscle cells, including those in your heart.</description>
        <time_frame>8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)</description>
          </group>
          <group group_id="O2">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Incidences of Hyperkalemia</title>
          <description>Hyperkalemia is defined as Potassium level &gt;5.5 mEq/L. Hyperkalemia is the medical term that describes a potassium level in your blood that's higher than normal. Potassium is a chemical that is critical to the function of nerve and muscle cells, including those in your heart.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Incidences of Angioedema</title>
        <description>Angioedema is a type of abrupt swelling that occurs under the skin and/or mucous membranes and is often localized to the head, neck, throat, and/or tongue, but may occur elsewhere, including the genitalia and intestines. Severe cases may be associated with difficulty in breathing.</description>
        <time_frame>8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)</description>
          </group>
          <group group_id="O2">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Incidences of Angioedema</title>
          <description>Angioedema is a type of abrupt swelling that occurs under the skin and/or mucous membranes and is often localized to the head, neck, throat, and/or tongue, but may occur elsewhere, including the genitalia and intestines. Severe cases may be associated with difficulty in breathing.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Sensitivity Troponin (Hs-Troponin)</title>
        <description>time-averaged (Weeks 4 and 8) change from baseline in hs-troponin T. hs-Troponin-T is a biomarker that is released from the heart under stress or injury conditions.</description>
        <time_frame>Baseline, Week 4/Week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)</description>
          </group>
          <group group_id="O2">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Sensitivity Troponin (Hs-Troponin)</title>
          <description>time-averaged (Weeks 4 and 8) change from baseline in hs-troponin T. hs-Troponin-T is a biomarker that is released from the heart under stress or injury conditions.</description>
          <population>FAS</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7477" lower_limit="0.6979" upper_limit="0.8010"/>
                    <measurement group_id="O2" value="0.6345" lower_limit="0.5920" upper_limit="0.6801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>ANCOVA</method>
            <param_type>exponentially back transformed from LS m</param_type>
            <param_value>0.8487</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7694</ci_lower_limit>
            <ci_upper_limit>0.9361</ci_upper_limit>
            <estimate_desc>Geometric Mean Ratio: Sacubitril/ Valsartan vs. Enalapril</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinary cGMP</title>
        <description>Time-averaged (Weeks 4 and 8) change from baseline in urinary cGMP. Urinary Cyclic GMP (cGMP) is a biomarker measured in the urine that reflects the activity of biomarkers such as BNP (Brain Natriuretic Peptide)</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)</description>
          </group>
          <group group_id="O2">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinary cGMP</title>
          <description>Time-averaged (Weeks 4 and 8) change from baseline in urinary cGMP. Urinary Cyclic GMP (cGMP) is a biomarker measured in the urine that reflects the activity of biomarkers such as BNP (Brain Natriuretic Peptide)</description>
          <population>FAS</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9641" lower_limit="0.8832" upper_limit="1.0524"/>
                    <measurement group_id="O2" value="1.5895" lower_limit="1.4554" upper_limit="1.7359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <param_type>expon. back transformed from LS means</param_type>
            <param_value>1.6487</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4559</ci_lower_limit>
            <ci_upper_limit>1.8669</ci_upper_limit>
            <estimate_desc>Geometric Mean Ratio: Sacubitril/ Valsartan vs. Enalapril</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinary cGMP to Urinary Creatinine Ratio</title>
        <description>Time-averaged (Weeks 4 and 8) change from baseline in urinary cGMP to urinary creatinine ratio.
Urinary cGMP to urinary creatinine ratio is how much urinary cGMP (which reflects natriuretic peptide activity) compared to a compound in the urine called creatinine (which helps your doctor evaluate how well your kidneys are functioning).</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)</description>
          </group>
          <group group_id="O2">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinary cGMP to Urinary Creatinine Ratio</title>
          <description>Time-averaged (Weeks 4 and 8) change from baseline in urinary cGMP to urinary creatinine ratio.
Urinary cGMP to urinary creatinine ratio is how much urinary cGMP (which reflects natriuretic peptide activity) compared to a compound in the urine called creatinine (which helps your doctor evaluate how well your kidneys are functioning).</description>
          <population>FAS</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8258" lower_limit="0.7870" upper_limit="0.8665"/>
                    <measurement group_id="O2" value="1.1714" lower_limit="1.1160" upper_limit="1.2296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <param_type>expon. back transformed from LS means</param_type>
            <param_value>1.4186</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3248</ci_lower_limit>
            <ci_upper_limit>1.5190</ci_upper_limit>
            <estimate_desc>Geometric Mean Ratio: Sacubitril/ Valsartan vs. Enalapril</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in BNP to NTproBNP Ratio</title>
        <description>Time-averaged (Weeks 4 and 8) change from baseline in BNP to NT-proBNP ratio. BNP and NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure. The test measuring BNP to NT-proBNP is measuring how much of each of these biomarkers are present in order to evaluate heart failure.</description>
        <time_frame>baseline, Week 4 and Week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)</description>
          </group>
          <group group_id="O2">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BNP to NTproBNP Ratio</title>
          <description>Time-averaged (Weeks 4 and 8) change from baseline in BNP to NT-proBNP ratio. BNP and NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure. The test measuring BNP to NT-proBNP is measuring how much of each of these biomarkers are present in order to evaluate heart failure.</description>
          <population>FAS</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9174" lower_limit="0.8728" upper_limit="0.9642"/>
                    <measurement group_id="O2" value="1.3527" lower_limit="1.2882" upper_limit="1.4204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <param_type>expon. back transformed from LS means</param_type>
            <param_value>1.4745</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3752</ci_lower_limit>
            <ci_upper_limit>1.5810</ci_upper_limit>
            <estimate_desc>Geometric Mean Ratio: Sacubitril/ Valsartan vs. Enalapril</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Change From Baseline at Week 8</title>
        <description>BNP and NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure. The test measuring BNP to NT-proBNP is measuring how much of each of these biomarkers are present in order to evaluate heart failure.
Plasma NT-proBNP (pg/mL) values were Week 8 visit.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>Full analysis set (FAS): consisted of all randomized patients with the exception for those patients who had not been qualified for randomization and had not received study treatment, but had been inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)</description>
          </group>
          <group group_id="O2">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement. Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).</description>
          </group>
        </group_list>
        <measure>
          <title>N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Change From Baseline at Week 8</title>
          <description>BNP and NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure. The test measuring BNP to NT-proBNP is measuring how much of each of these biomarkers are present in order to evaluate heart failure.
Plasma NT-proBNP (pg/mL) values were Week 8 visit.</description>
          <population>Full analysis set (FAS): consisted of all randomized patients with the exception for those patients who had not been qualified for randomization and had not received study treatment, but had been inadvertently randomized into the study.</population>
          <units>pg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6443" lower_limit="0.5815" upper_limit="0.7410"/>
                    <measurement group_id="O2" value="0.4596" lower_limit="0.4150" upper_limit="0.5089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>ANCOVA model for a log-scaled response with treatment group as a class variable and biomarker baseline value in logarithmic scale as a continuous covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>expon. back transformed from LS means</param_type>
            <param_value>0.7133</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6171</ci_lower_limit>
            <ci_upper_limit>0.8245</ci_upper_limit>
            <estimate_desc>Geometric Mean Ratio: Sacubitril/Valsartan vs. Enalapril</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events and serious adverse events were collected for the maximum actual duration of treatment exposure and follow up for a participant per the protocol for approximately 85 days.</time_frame>
      <desc>All cause mortality (deaths) was collected for as long as participants could be contacted from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV) up to a maximum of 85 days.
Data reported on the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Double Blind Phase Enalapril</title>
          <description>Patients who received Enalapril in the double-blind phase.</description>
        </group>
        <group group_id="E2">
          <title>Double Blind Phase Sacubitril/Valsartan</title>
          <description>Patients who received Sacubitril/Valsartan in the double-blind phase.</description>
        </group>
        <group group_id="E3">
          <title>Open-Label Phase Sacubitril/Valsartan</title>
          <description>All patients who received sacubitril/valsartan in the open-label phase.</description>
        </group>
        <group group_id="E4">
          <title>Pooled Phase Sacubitril/Valsartan</title>
          <description>All patients who received a dose of sacubitril/valsartan either in the double-blind phase or open-label phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="191" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cardiac sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Long QT syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Subarachnoid haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Vascular headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Lead dislodgement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pulmonary ossification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hypoperfusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="199" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="828"/>
                <counts group_id="E4" subjects_affected="97" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

